NCT01332188

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

A Single Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy of Three Different Concentrations of Cetirizine (0.05%, 0.1%, and 0.24%) Ophthalmic Solution Versus Vehicle in the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model (CAC)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Aciex Therapeutics, Inc. · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.

Conditions

• Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	AC-170 0.05%	1 drop in each eye at 3 separate times during a 21 day period
DRUG	AC-170 0.1%	1 drop in each eye at 3 separate times during a 21 day period
DRUG	AC-170 0.24%	1 drop in each eye at 3 separate times during a 21 day period
DRUG	AC-170 0%	1 drop in each eye at 3 separate times during a 21 day period

Timeline

• Start date: 2011-04-01
• Primary completion: 2011-06-01
• Completion: 2011-10-01
• First posted: 2011-04-11
• Last updated: 2017-08-30
• Results posted: 2017-08-30

Locations

1 site across 1 country: United States